Highest-materiality recent filing
American Vanguard Q2 net loss widens to $9.9M, reaffirms FY guidance
Q2 net sales $117M vs $129M YoY; operating loss $0.30M vs income $4.4M; net loss $9.9M vs $0.849M.
AVD awards $450K in success bonuses to executives for completing total debt restructuring
Board approves success bonuses totaling $450K: Douglas Kaye $150K, David Johnson $125K, Timothy Donnelly $125K, Shirin Khosravi $50K for restructuring all company debt.
American Vanguard enters $285M term loan facility to refinance existing debt
New $225M first lien term loan at SOFR+8.25% (or Base+7.25%) with step-downs; $60M second lien at SOFR+2.00% (3.00% floor).
Net sales $515M vs $547M in 2024; GAAP net loss improved to $50M from $126M.
American Vanguard Q3 net loss narrows, EBITDA improves; reaffirms FY2025 guidance
Q3 net sales $119M flat YoY; gross margin jumped to 29% from 15%.
Maturity extended from Aug 5, 2026 to Dec 31, 2026; borrowing capacity steps down from $245M to $180M by year-end.
American Vanguard Q2 adj EBITDA rises 83% to $11M; reiterates FY guidance
Net sales of $129M (+1% YoY); GAAP EPS $(0.03) vs $(0.42); adjusted EBITDA $11M vs $6M.
American Vanguard regains NYSE compliance; Q1 earnings transcript lacks financial details in filing
NYSE closed April 2 non-compliance notice after company filed Form 10-K and Q1 2025 10-Q.
American Vanguard Q1 net sales $115.8M, EPS ($0.30); Adjusted EBITDA $3.0M down from $15.5M
Net sales of $115.8M, down 14% YoY from $135.1M; GAAP EPS of $(0.30) vs $0.06.
AVD credit amendment extends filing deadlines, reduces revolver by $60M, waives default
FY2024 audited financials deadline extended to 150 days (from 120); Q1 2025 quarterly to 60 days (from 45).
American Vanguard FY2024 adj. EBITDA $42M; guides 2025 revenue $565-$585M
Preliminary Q4 2024 net sales ~$169M vs $172M in Q4 2023; adjusted EBITDA ~$18M vs $22M.
AMVAC Chemical amends credit facility; loosens leverage covenants, restricts dividends and buybacks
Maximum Total Leverage Ratio raised to 6.25x for Q1/Q2 2025, then 5.75x for Q3, returning to 3.25x year-end.
American Vanguard appoints Dak Kaye as CEO effective Dec 9; base salary $650K
Douglas A. ("Dak") Kaye III named CEO effective Dec 9, 2024, succeeding the Office of CEO.
American Vanguard Q3 net sales $118.3M, Adj. EBITDA $1.8M, EPS -$0.92; maintains FY guidance
Net sales $118.3M vs $149.5M YoY; GAAP EPS ($0.92) vs ($0.01).
American Vanguard withdraws Dacthal registrations after EPA suspension based on rodent study
Voluntary cancellation of Dacthal federal registrations submitted to EPA after emergency suspension order on Aug 6, 2024.
American Vanguard Q2 EPS -$0.42; cuts FY2024 EBITDA guidance to $40-50M; EPA suspends Dacthal
Net sales $128.2M vs $132.8M Q2; Adj EBITDA $6.2M vs $10.7M; EPS $(0.42) vs $(0.04).
CEO Eric Wintemute concluded his role effective July 12, 2024; remains Chairman until 2025 annual meeting and will consult part-time.
American Vanguard CEO Eric Wintemute to retire; successor search by Dec 31, 2024
Eric Wintemute to retire as CEO; successor search by Kincannon & Reed.
Net sales $135M (+8% YoY); diluted EPS $0.06 vs $0.07; net income $1.6M vs $1.9M.
AVD reports Q4 net sales $172.2M, EPS $0.25; FY sales $579M; guides 2024 EBITDA $70-80M
Q4 net sales $172.2M (+8% YoY), EPS $0.25 vs $0.13, adjusted EBITDA $21M.
American Vanguard reaffirms FY2024 outlook; achieves debt-to-EBITDA target; Q4 sales up 8% YoY
Q4 2023 net sales up ~8% YoY; full-year net sales down 5% vs 2022; gross margins and adjusted EBITDA in line with forecast.
American Vanguard posts Q3 net loss of $325k; amends credit covenants to ease leverage ratios
Q3 net sales $149.5M flat YoY; net loss $0.3M vs profit $6.7M a year ago; EPS ($0.01).
American Vanguard Q2 net loss of $1.05M; 2023 guidance lowered; lender waiver on covenant default
Q2 net sales $132.8M (down 10.4% YoY); net loss $1.05M vs net income $6.83M; EPS -$0.04.
American Vanguard authorizes $15M share repurchase program over next 12 months
Board approved repurchase of up to $15M of common stock over twelve months under Rule 10b-18.
AVD Q1 net sales down 17%, EPS $0.07 vs $0.33 YoY; credit covenant amended
Q1 net sales $124.9M (down 17% YoY); net income $1.9M (down 81%); adjusted EBITDA $11.5M (down 50%).
American Vanguard FY 2022 net sales +9% to $610M, net income +47%, guides FY 2023 growth
Net sales $610M (+9%), net income $27.4M (+47%), diluted EPS $0.92 (+51%).
Preliminary FY2022 adjusted EBITDA expected $73-75M, down from prior guidance of $80M but up 15-18% vs 2021.
American Vanguard Q3 EPS $0.23 (+27.8% YoY); adj. EBITDA view ~$80M
Q3 net sales $152M (+3.4% YoY), net income $6.7M (+21.8%), diluted EPS $0.23.
American Vanguard announces $20M accelerated share repurchase plan
Company enters $20M ASR in addition to existing March 14, 2022 10b5-1 plan.
American Vanguard Q2 EPS $0.23 beats consensus; raises FY22 adj. EBITDA target to $79-81M
Q2 net sales $148M (+10% YoY); net income $6.8M (+33% YoY); diluted EPS $0.23 vs $0.17 YoY.
AVD updates 2022 targets: net income +60-70%, revenue +8-11%; 1H net income +104%
2022 full-year targets: net income +60-70%, revenue +8-11%, gross margin 38-40%.
American Vanguard elects nine directors in contested vote, declares $0.025 quarterly dividend
Nine directors elected; three from dissident Cruiser Capital slate (Bassett, Gottschalk, Rosenbloom).
American Vanguard sends letter urging stockholders to vote for its board slate amid proxy contest
Stock YTD up 37% vs Russell 2000 down 19% as of May 20, 2022.
American Vanguard sends letter to stockholders defending board, urging vote against Cruiser nominees
Annual Meeting set for June 1, 2022; board unanimously urges vote FOR ALL nine WHITE proxy card nominees.
American Vanguard discloses contested proxy solicitation for 2022 Annual Meeting
Presentation filed as Exhibit 99.5 regarding contested proxy solicitation for 2022 Annual Meeting of Stockholders.
Q1 net sales $149.4M (+28.6% YoY), net income $9.9M (+219%), EBITDA $22.9M (+64.7%).
Effective as of July 12, 2024, Eric Wintemute concluded his role as Chief Executive Officer of American Vanguard Corporation (the “Company”).
Mr. Donnelly has also been designated as, and assumed the duties of, the Company’s Acting Chief Executive Officer and acting principal executive officer as of July 12, 2024.
Effective as of July 3, 2024, American Vanguard Corporation (the “Company” or “Registrant”) and Eric Wintemute, the Company’s Chairman and CEO, entered into a Transition Agreement, which set forth the terms and conditions of Mr. Wintemute’s retirement.
On March 7, 2024, American Vanguard Corporation (“Registrant”) issued a press release announcing that Morton D. Erlich had retired from Registrant’s board of directors
Registrant announced its board of directors had appointed Steven Macicek to fill the vacancy to be created by Mr. Erlich’s departure and to commence service on its board effective after the close of business on day upon which Mr. Erlich’s retirement is deemed to be effective (which, in all probability) will be March 15, 2024.
Lawrence S. Clark, who has served on the Registrant’s board of directors since 2006, has submitted a resignation from the board and its committees effective close of business on Thursday, December 9, 2021.
Registrant announced its board of directors had appointed Marisol Angelini to fill the vacancy to be created by Mr. Clark’s departure and to commence service on its board effective after the close of business on Thursday, December 9, 2021.
Max materiality 0.85 · Median 0.68 · Most common event earnings